Acute Myeloid Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Acute Myeloid Leukemia stocks.

Acute Myeloid Leukemia Stocks Recent News

Date Stock Title
Nov 7 CRDF Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 7 ACLX Arcellx price target raised to $106 from $81 at Morgan Stanley
Nov 7 ACLX Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Nov 6 MRUS Merus to Present at Upcoming Investor Conferences
Nov 6 ARGX Peering Into argenx's Recent Short Interest
Nov 6 ACLX Navigating 7 Analyst Ratings For Arcellx
Nov 6 GLYC GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
Nov 5 MRUS Merus: Petosemtamab Set Up For December 2024 Data Presentation
Nov 5 ARGX Why Argenx (ARGX) Might be Well Poised for a Surge
Nov 5 ACLX Arcellx issues updates on anito-cel clinical trials
Nov 5 ACLX Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
Nov 5 ERAS Erasca to Present at Upcoming Investor Conferences
Nov 5 ACLX Cancer cell therapy from Arcellx, Gilead shows promise in early data
Nov 5 MRUS Merus says FDA extended review period for cancer drug
Nov 5 MRUS Merus Receives FDA extension of PDUFA for zenocutuzumab
Nov 5 ARGX argenx to Participate at Upcoming Investor Conferences
Nov 4 ATNM Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
Nov 4 ARGX Three Value Stocks Priced Below Estimated Worth In November 2024
Nov 4 ARGX High Growth Tech Stocks To Watch In November 2024
Nov 2 GLYC M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.Risk factors include smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, and exposure to the chemical benzene. The underlying mechanism involves replacement of normal bone marrow with leukemia cells, which results in a drop in red blood cells, platelets, and normal white blood cells. Diagnosis is generally based on bone marrow aspiration and specific blood tests. AML has several subtypes; for which treatments and outcomes may vary.AML, typically is initially treated with chemotherapy aimed at inducing remission. People may then go on to receive additional chemotherapy, radiation therapy, or a stem cell transplant. The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive. Arsenic trioxide may be tried in cases that have recurred following usual treatments.AML affected about one million people globally in 2015 and resulted in 147,000 deaths. It most commonly occurs in older adults. Males are affected more often than females. AML is curable in about 35% of people under 60 years old and 10% over 60 years old. Older people who are not healthy enough to receive intensive chemotherapy have a typical survival of 5–10 months. It accounts for roughly 1.8% of cancer deaths in the United States.

Browse All Tags